Drug · CHEMBL1201577

CETUXIMAB

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. CETUXIMAB. Drugs and targets, record CHEMBL1201577. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1201577

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: CETUXIMAB; ChEMBL
ChEMBL ID: CHEMBL1201577; ChEMBL
Type: Antibody; ChEMBL
Brand names: Erbitux; ChEMBL
Other names: ABP-494, C-225, C225, CMAB-009, CMAB009, Cetuximab (genetical recombination), Cetuximab biosimilar (abp-494), IMC-225, IMC-C225, MOAB C225; ChEMBL
Open Targets' highest stage: Approval, for 8 of its 114 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Targets1

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
EGFR	Epidermal growth factor receptor	Epidermal growth factor receptor erbB1 inhibitor	INHIBITOR	https://conductscience.org/library/genes/1956

Source ChEMBL

Diseases114

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
colorectal cancer	Approval	TTD	321	320	https://conductscience.org/library/drugs?q=MONDO_0005575
head and neck squamous cell carcinoma	Phase 3	ClinicalTrials.gov	194	194	https://conductscience.org/library/drugs?q=MONDO_0010150
non-small cell lung carcinoma	Phase 3	ClinicalTrials.gov	80	80	https://conductscience.org/library/drugs?q=MONDO_0005233
head and neck cancer	Phase 3	ClinicalTrials.gov	44	44	https://conductscience.org/library/drugs?q=MONDO_0005627
metastatic colorectal cancer	Phase 3	ClinicalTrials.gov	26	26	https://conductscience.org/library/drugs?q=EFO_1001480
rectal cancer	Phase 2	ClinicalTrials.gov	23	23	https://conductscience.org/library/drugs?q=MONDO_0006519
colorectal carcinoma	Approval	PMDA	22	21	https://conductscience.org/library/drugs?q=MONDO_0024331
oropharynx squamous cell carcinoma	Phase 3	ClinicalTrials.gov	17	17	https://conductscience.org/library/drugs?q=MONDO_0044704
malignant colon neoplasm	Phase 3	ClinicalTrials.gov	16	16	https://conductscience.org/library/drugs?q=MONDO_0021063
esophageal cancer	Phase 3	ClinicalTrials.gov	15	15	https://conductscience.org/library/drugs?q=MONDO_0007576

1 to 10 of 114Source Open Targets

See all 114 diseases

Trials968

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 6 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00079274	Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer	Phase 3	3,397	2015-02-09	cetuximab	Its name	ClinicalTrials.gov
NCT00265850	Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer	Phase 3	2,334	2017-04-26	cetuximab	Its name	ClinicalTrials.gov
NCT00148798	Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)	Phase 3	1,861	2011-10-04	cetuximab	Its name	ClinicalTrials.gov
NCT00946712	S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer	Phase 3	1,333	2019-03-07	cetuximab	Its name	ClinicalTrials.gov
NCT00154102	Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)	Phase 3	1,221	2011-02-23	cetuximab	Its name	ClinicalTrials.gov
NCT02291289	A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)	Phase 2	1,044	2020-07-24	cetuximab	Its name	ClinicalTrials.gov
NCT01001377	ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer	Phase 3	1,010	2014-03-24	cetuximab	Its name	ClinicalTrials.gov
NCT01302834	Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer	Phase 3	987	2020-01-09	cetuximab	Its name	ClinicalTrials.gov
NCT00265941	Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer	Phase 3	940	2017-12-21	cetuximab	Its name	ClinicalTrials.gov
NCT00095199	Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer	Phase 3	939	2012-10-15	cetuximab	Its name	ClinicalTrials.gov

1 to 10 of 968

See all 968 trials

Comparisons in its trials167

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm I (Chemo +/- Bevacizumab) vs Arm II (Chemo, Cetuximab, +/- Bevacizumab): deaths from any cause	593 of 657	570 of 656	1,313	NCT00946712	Trial comparisons
Arm I (Chemo +/- Bevacizumab) vs Arm II (Chemo, Cetuximab, +/- Bevacizumab): serious adverse events	66 of 632	97 of 627	1,259	NCT00946712	Trial comparisons
Cetuximab Plus FOLFIRI vs FOLFIRI Alone: Safety - Number of Patients Experiencing Any Adverse Event	599 of 600	597 of 602	1,202	NCT00154102	Trial comparisons
Cetuximab Plus FOLFIRI vs FOLFIRI Alone: serious adverse events	263 of 600	204 of 602	1,202	NCT00154102	Trial comparisons
Cetuximab Plus FOLFIRI vs FOLFIRI Alone: Participants With No Residual Tumor After Metastatic Surgery	29 of 599	10 of 599	1,198	NCT00154102	Trial comparisons
Arm A: FOLFOX or FOLFIRI + Bevacizumab vs Arm B: FOLFOX or FOLFIRI + Cetuximab: serious adverse events	98 of 559	111 of 578	1,137	NCT00265850	Trial comparisons
Cetuximab Plus Chemotherapy vs Chemotherapy Alone: Safety - Number of Patients Experiencing Any Adverse Event	545 of 548	549 of 562	1,110	NCT00148798	Trial comparisons
Cetuximab Plus Chemotherapy vs Chemotherapy Alone: serious adverse events	325 of 548	244 of 562	1,110	NCT00148798	Trial comparisons
Cetuximab vs Panitumumab: serious adverse events	169 of 503	151 of 496	999	NCT01001377	Trial comparisons
RT + Cisplatin vs RT + Cisplatin + Cetuximab: serious adverse events	208 of 447	237 of 444	891	NCT00265941	Trial comparisons

1 to 10 of 167

See all 167 comparisons in its trials

Papers from its trials480

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41389341	RESULT	1	PubMed
37311055	RESULT	1	PubMed
34418665	RESULT	1	PubMed
34359048	RESULT	1	PubMed
34031056	RESULT	1	PubMed
32766143	RESULT	1	PubMed
31841363	RESULT	1	PubMed
31331370	RESULT	1	PubMed
30449625	RESULT	1	PubMed
30406032	RESULT	1	PubMed

1 to 10 of 480

See all 480 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL1201577

GET https://conductscience.org/api/drugs/v1/CHEMBL1201577/diseases?page=2

API reference For AI assistants